Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Explore how pharmaceutical internal audits and GMP audit checklist practices enhance inspection readiness, strengthen pharmaceutical quality system compliance, and reduce recurring audit findings. Learn how data integrity controls and structured audit processes support effective regulatory audit performance.
This article explains the regulatory relationship between CMC and GMP, highlighting key differences, inspection findings, and compliance expectations. It shows how documentation, validation, and manufacturing control connect to FDA and global pharmaceutical quality system requirements.
This article explains how equipment qualification supports GMP compliance through structured validation stages. It highlights common inspection findings, documentation requirements, and risk-based validation lifecycle approach to help reduce validation deviation trends pharma inspections and improve audit readiness.
This article provides a practical overview of GMP regulations in 2026, covering FDA 21 CFR 210/211, EU GMP guidelines EudraLex Volume 4, and WHO expectations. It explains inspection trends, audit readiness, and regulatory compliance gaps in pharmaceutical manufacturing systems.
This article explains how GMP inspections are structured using the PICS guideline, focusing on checklist execution, data integrity controls, and system-level compliance gaps. It highlights real inspection expectations and how companies can improve audit readiness effectively.
This article explores computerized system compliance in pharmaceutical environments, focusing on validation lifecycle, audit trail integrity, and risk-based approaches. It highlights regulatory expectations for electronic records, system controls, and inspection readiness under EU GMP frameworks and GxP standards.